Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06197334
Recruiting Not applicable

Gastro-intestinal Biopotential Recorder by Means of Surface ELEctrodes

NCT06197334 · tracked via the Priya Life Science France tracker
Sponsor
Central Hospital, Nancy, France
Phase
Not applicable
Started
2025-02-18
Last updated
2026-06-24

Condition(s) studied

Crohn DiseaseFunctional Gastrointestinal DisordersHealthy

Investigational drug(s) / intervention(s)

Gastro-intestinal biopotentials recording

Gastro-intestinal biopotentials recording: Participants will undertake two recordings made with the device. The first one will last 1 hour and 30 minutes and will occurs while the participants are fasting. Then, they will eat a standardized meal. Finally, the second recording will take place after the meal ingestion and will last 1 hour and 30 minutes while the participants are in postprandial state.

Study summary

The goal of this clinical trial is to compare the gastro-intestinal biopotentials recorded with a homemade device using surface electrodes placed on the abdomen in healthy volunteers, Crohn's disease patients without fibrosis, Crohn's disease patients with fibrosis and in functional gastrointestinal disorders (FGID) patients.

The main question it aims to answer is:

• Is there any differences in the gastro-intestinal biopotentials between the different populations under study?

It aims to answer two secondary questions:

* Are the gastro-intestinal biopotentials comparable to the Harvey-Bradshaw Index, MRI and biological data for patients with Crohn's disease?
* Are the gastro-intestinal biopotentials comparable to Rome IV criteria for functional gastrointestinal disorders patients?

Participants will undertake two recordings made with the device. The first one will last 1 hour and 30 minutes and will occurs while the participants are fasting. Then, the participants will eat a standardized meal. Finally, the second recording will take place after the meal ingestion and will last 1 hour and 30 minutes while the participants are in postprandial state.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria for all participants: * Person age \> 18 years * Person has been fasting for at least 12 hours * Person who has received full information on the organization of the research and has not objected to the use of this data. * Person affiliated to or beneficiary of a social security plan * Person informed about study organization and having signed the informed consent Inclusion Criteria for healthy volunteers : * Person has no history of chronic gastro-intestinal disease * Person has no acute of gastro-intestinal disease Inclusion Criteria for Crohn's disease patients without fibrosis : * Person is already diagnosed with Crohn's disease * Person has underwent during the last 6 months : * An MRI showing no fibrosis * A blood test for C-reactive protein and fecal calprotectine * A questionnaire to asses the Harvey-Bradshaw Index Inclusion Criteria for Crohn's disease patients with fibrosis : * Person is already diagnosed with Crohn's disease * Person has underwent during the last 6 months : * An MRI showing fibrosis * A blood test for C-reactive protein and fecal calprotectine * A questionnaire to asses the Harvey-Bradshaw Index Inclusion Criteria for functional gastrointestinal disorders patients : * Person is already diagnosed with functional gastrointestinal disorders * Person has underwent an evaluation of the Rome IV criteria Exclusion Criteria for all participants: * Person having a pacemaker * Person suffering from a sensory disorder making insensitive to pain on the skin * Person suffering from a mental or motor disorders creating uncontroled movements * Person being allergic to one or more component of the device * Person being allergic to : soy, dairy food, peanuts, wheat, nuts * Person having an history of gastro-intestinal surgery * Person suffering from injury or erythema on the abdominal skin * Person having a contagious potential (bacterial, fungal or viral) * Person being in menstruation period * Person suffering from urinary incontinence * Minor (not emancipated) * Person of legal age (subject to a legal protection measure) * Adult unable to give consent

Primary outcome measure(s)

  • Gastro-intestinal biopotentials pattern as recorded by the homemade recorder — 12 months
    Gastro-intestinal biopotentials pattern in patients versus healthy volunteers

Trial sites (2)

FacilityCityRegionStatus
CHRU Nancy Vandœuvre-lès-Nancy CHRU de Nancy Recruiting
CHRU de Nancy - Brabois Vandœuvre-lès-Nancy France Recruiting

More Central Hospital, Nancy, France trials in France

New CSF Biomarkers for Alzheimer's Disease Recruiting
Effect of Early Empagliflozin Initiation in Cardiogenic Shock. Active, not recruiting
Contribution of Contrast Enhanced Ultrasound for Diagnosis of Adnexal Torsion Recruiting
One-Year Effect on Levodopa Equivalent Daily Dose of Thalamic VIM Nucleus Stimulation Compared to Subthalamic Nucleus Stimulation in Patients With Parkinson's Disease Starting soon
Acute Heart Failure With Reduced Ejection Fraction - COngestion Discharge Evaluation Recruiting

Other trials for the same condition

Cerebello-motor Neuromodulation After Stroke. CERSTIM. Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease Recruiting
Pre-analytical Processing of Human Samples for Microbiota Analysis Quality Starting soon
Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal Recruiting
Evaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06197334 on ClinicalTrials.gov ↗ ← All trials in France